A study on the correlation between the mean platelet volume to monocyte count ratio and long-term prognosis in patients with newly diagnosed coronary artery disease
Open Access
- 9 October 2025
- journal article
- clinical trial-article
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 12, 1643542
Abstract
Background: Coronary atherosclerotic heart disease (CAD) remains a major global health burden and a leading cause of mortality. Its pathogenesis is closely linked to multiple risk factors, among which inflammation plays a central role. While inflammatory biomarkers such as platelet and monocyte counts have been incorporated into prognostic assessments, their predictive accuracy remains limited. Further investigation of novel inflammatory indices is needed to refine risk stratification and guide clinical management. Objective: This study aimed to evaluate the prognostic value of the mean platelet volume-to-monocyte count ratio (MMR) for predicting major adverse cardiovascular events (MACE) in patients with newly diagnosed CAD. Methods: A total of 652 treatment-naïve CAD patients were enrolled. Kaplan–Meier survival analysis and univariate Cox proportional hazards models were applied to assess the association between MMR levels and MACE. Subgroup analyses were performed to test for effect modification. Restricted cubic spline (RCS) models were used to explore the dose–response relationship. The incremental predictive value of MMR beyond conventional risk factors was examined using changes in the concordance index (C-index), net reclassification improvement (NRI), and integrated discrimination improvement (IDI). Results: Patients were stratified into quintiles based on MMR values (L1: 7.89–14.43; L2: 14.50–17.96; L3: 18.00–22.16; L4: 22.25–28.53; L5: 28.67–60.67). Kaplan–Meier analysis revealed significantly poorer outcomes in the L3 group compared with other quintiles (log-rank P = 0.0014). RCS analysis demonstrated a significant nonlinear association between MMR levels and MACE risk ( P = 0.001), characterized by an inverted U-shaped relationship. Incorporating MMR into conventional risk models significantly improved predictive performance (AUC 0.718 vs. 0.673; P = 0.018). Conclusion: In newly diagnosed CAD patients, MMR shows a nonlinear, inverted U-shaped association with MACE risk. The addition of MMR to standard risk models enhances prognostic accuracy. Further multicenter prospective studies and mechanistic trials are needed to verify the prognostic value of MMR and to elucidate its mechanism of action.Keywords
This publication has 41 references indexed in Scilit:
- Association of immune-inflammatory biomarkers during pregnancy and the postpartum period with postpartum depression symptoms: A cross-sectional and longitudinal retrospective analysisBrain, Behavior, and Immunity, 2025
- Do platelets protect the heart against ischemia/reperfusion injury or exacerbate cardiac ischemia/reperfusion injury? The role of PDGF, VEGF, and PAFLife Sciences, 2024
- SEMA4D/VEGF surface enhances endothelialization by diminished-glycolysis-mediated M2-like macrophage polarizationMaterials Today Bio, 2023
- MO32-7 High ALC, low NLR and PLR are associated with longer OS in patients with metastatic breast cancer treated with eribulinAnnals of Oncology, 2021
- Platelet and Endothelial Activation as Potential Mechanisms Behind the Thrombotic Complications of COVID-19 PatientsJACC: Basic To Translational Science, 2021
- Impact of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio on 5-Year Clinical Outcomes of Patients with Stable Coronary Artery Disease Undergoing Elective Percutaneous Coronary InterventionJournal of Cardiovascular Translational Research, 2018
- Macrophages in atherosclerosis: a dynamic balanceNature Reviews Immunology, 2013
- The immune system in atherosclerosisNature Immunology, 2011
- Role of Reticulated Platelets and Platelet Size Heterogeneity on Platelet Activity After Dual Antiplatelet Therapy With Aspirin and Clopidogrel in Patients With Stable Coronary Artery DiseaseJACC, 2008
- Inflammation and atherosclerosis: role of C-Reactive protein in risk assessmentThe American Journal of Medicine, 2004